Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level
July 30 2020 - 7:00AM
Trillium Therapeutics Inc. (“Trillium” or the “Company”)
(NASDAQ/TSX:TRIL), a clinical stage immuno-oncology
company developing innovative therapies for the treatment of
cancer, provided an update today on its ongoing phase 1b dose
optimization study of TTI-621 in patients with relapsed and/or
refractory cutaneous T-cell lymphoma (CTCL). TTI-621 is an innate
immune checkpoint inhibitor targeting CD47, a “don’t eat me” signal
that cancer cells use to evade destruction by the immune system.
“We are pleased to report that we have
successfully completed the safety assessment part of the 1.4 mg/kg
cohort, with no DLTs observed,” said Jan Skvarka, President and
Chief Executive Officer of Trillium. “After experiencing a
temporary slow-down in patient enrollment due to Covid-19, we are
now moving ahead with the 2.0 mg/kg dose level, and anticipate
dosing the first patient in early August 2020.”
TTI-621 Phase 1b Study
Update
- 15 relapsed/refractory CTCL patients have been enrolled in the
first 4 cohorts, and were treated with TTI-621 monotherapy at doses
up to 1.4 mg/kg.
- Dose limiting toxicity (DLT) evaluation of Cohort 4 (1.4 mg/kg
dose level) has been successfully completed and dose escalation is
now continuing at 2.0 mg/kg.
- Data related to clinical activity, pharmacokinetics and
pharmacodynamics are not yet available for the 1.4 mg/kg
cohort.
Trillium intends to provide an update on its
TTI-621 and TTI-622 studies at the American Society for Hematology
Annual Meeting in December 2020.
About TTI-621
TTI-621 is a SIRPαFc decoy receptor consisting
of the CD47-binding domain of human SIRPα linked to an IgG1 Fc
region. It is designed to enhance phagocytosis and anti-tumor
activity by preventing CD47 from delivering its inhibitory signal.
Importantly, TTI-621 does not bind appreciably to human red blood
cells, providing a key differentiation feature.
About Trillium Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
Company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “don’t eat me” signal that cancer cells frequently use to
evade the immune system.
For more information visit:
www.trilliumtherapeutics.com
Caution Regarding Forward-Looking
Information
This press release contains forward-looking
statements within the meaning of applicable United States
securities laws and forward-looking information within the meaning
of Canadian securities laws (collectively, "forward-looking
statements"). Forward-looking statements in this press release
include statements about, without limitation, the expected dosing
of patients in August 2020 and the timing of the release of further
data on Trillium’s TTI-621 and TTI-622 studies. With respect to the
forward-looking statements contained in this press release,
Trillium has made numerous assumptions regarding, among other
things: the impact of the Covid-19 pandemic on its operations, the
effectiveness and timeliness of clinical trials; and the
completeness, accuracy and usefulness of the data. While Trillium
considers these assumptions to be reasonable, these assumptions are
inherently subject to significant scientific, business, economic,
competitive, market and social uncertainties and contingencies.
Additionally, there are known and unknown risk factors that could
cause Trillium's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements
contained in this press release. A discussion of risks and
uncertainties facing Trillium appears in Trillium's Annual
Information Form for the year ended December 31, 2019 filed with
Canadian securities authorities and on Form 40-F with the U.S.
Securities Exchange Commission, each as updated by Trillium's
continuous disclosure filings, which are available at
www.sedar.com and at www.sec.gov. All forward-looking
statements herein are qualified in their entirety by this
cautionary statement, and Trillium disclaims any obligation to
revise or update any such forward-looking statements or to publicly
announce the result of any revisions to any of the forward-looking
statements contained herein to reflect future results, events or
developments, except as required by law.
Company Contact:James
ParsonsChief Financial OfficerTrillium Therapeutics Inc.
416-595-0627 x232james@trilliumtherapeutics.com
www.trilliumtherapeutics.com
Media Contact:Mike Beyer Sam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Jul 2023 to Jul 2024